Webcast Alert: GlycoGenesys, Inc. (GLGS) Presentation At RedChip Resources and Moors & Cabot's Small-Cap Investor Conference BOSTON, March 1 /PRNewswire-FirstCall/ -- GlycoGenesys, Inc. announces the following Webcast: What: GLGS Presentation at RedChip Resources and Moors & Cabot's Small-Cap Investor Conference When: 3/3/04 @ 12:00 p.m. EST Where: http://www.firstcallevents.com/service/ajwz400871954gf12.html How: Live over the Internet -- Simply log on to the web at the address above. If you are unable to participate during the live webcast, the call will be archived at http://www.firstcallevents.com/service/ajwz400871954gf12.html . GlycoGenesys, Inc. GlycoGenesys is a biotechnology company that develops and licenses products based on glycobiology. The Company's human therapeutic product GCS- 100, a unique compound to treat cancer, has been evaluated in Phase II(a) human clinical trials for both colorectal and pancreatic cancers. The Company most recently completed a Phase I dose escalation trial of GCS-100 up to 80 mg/m2 at Sharp Clinical Oncology Research in San Diego, California. Further information is available on GlycoGenesys' web site: http://www.glycogenesys.com/. Safe Harbor Statement Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including, but not limited to, risks of product development (such as failure to demonstrate efficacy or safety), risk related to FDA and other regulatory procedures, market acceptance risks, the impact of competitive products and pricing, the results of current and future licensing, joint ventures and other collaborative relationships, the results of financing efforts, developments regarding intellectual property rights and litigation, and other risks identified in the Company's Securities and Exchange Commission filings. Actual results, events or performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Contact: GlycoGenesys John W. Burns, 617-422-0674 Senior Vice President and CFO Rick Pierce, 617-422-0674 VP of Business Development (Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp , or the Real Player software, downloadable free from http://www.real.com/realone/index.html?lang=en&loc=us , and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to .) http://www.firstcallevents.com/service/ajwz400871954gf12.htmlDATASOURCE: GlycoGenesys Inc. CONTACT: John W. Burns, Senior Vice President and CFO of GlycoGenesys Inc., +1-617-422-0674 Web Site: http://www.glycogenesys.com/

Copyright